WAY enters the final week of August with an uncomfortable tension at its core: the founder-CEO has been selling shares steadily into a stock that is up 7.5% over the past month, while the Street's bull consensus remains firmly intact and analysts are still trimming their targets after a bruising earnings print.
The insider story is worth dwelling on. CEO Matt Hawkins has sold shares in four separate tranches since mid-July, offloading a combined ~153,000 shares for proceeds of roughly $3.7 million at prices ranging from $23.09 to $25.04. The most recent sales came on August 11 and 13 — shortly before Tuesday's 4.5% single-day drop to $24.21. Hawkins is classified as the company's founder, which means some of this activity may reflect pre-planned diversification rather than a directional view. But the frequency and the concentration of selling near recent highs gives the pattern a harder edge than routine housekeeping. The 90-day net insider figure shows nearly 245,000 shares sold net — no buying to offset the flow anywhere in the recent trade history.
The positioning picture in the lending market is notably relaxed. Short interest at 6.8% of the free float is meaningful but has been unwinding for weeks — down roughly 6.4% over the past month and another 3.8% on the week — settling at around 13 million shares. Borrow is cheap at 0.53% cost-to-borrow, itself off 17% over the past month. Availability is comfortable at 246% of current short interest, meaning for every share already borrowed there are roughly 2.5 more available — a long way from any kind of squeeze setup. Options traders are equally relaxed: the put/call ratio of 0.47 is fractionally below its 20-day average, essentially flat, and the PCR has drifted lower since early August when it was running closer to 0.55. There is no defensiveness building in the options market despite the CEO selling.
Analysts are bullish but reachable, not enthused. The mean price target is $33.09 against a current price of $24.21 — roughly 37% implied upside — but that headline figure obscures a run of downward revisions. After the July 30 earnings print, multiple houses cut their targets: Wells Fargo dropped from $36 to $33 (keeping Overweight), UBS went from $37 to $33 (Buy), and Truist Securities followed on August 13 with a cut from $38 to $33 (Buy). Barclays moved in the opposite direction earlier this month, nudging from $25 to $27 while reiterating Overweight. Needham reiterated a $33 Buy target this week. The message from the Street is consistent: still constructive, but progressively recalibrating the bar downward. The Benzinga bear case flags high labor costs, administrative complexity in the revenue cycle industry, and competitive pressure from AI automation as the structural risks. Bulls counter with strong cloud revenue growth and the company's AI-enabled workflow tools as a differentiation point. The ORTEX short score at 60.5 sits in the moderate-to-high range, up notably from recent weeks, a sign the data is leaning toward continued short pressure even as the raw SI count declines.
The earnings history adds context. The July 30 print triggered a 13.9% single-day drop, and the five-day move was still negative at -4.7%. An earlier event in the same cycle produced an 11.6% one-day decline. The pattern for WAY around results is sharp initial selling followed by partial recovery — the stock has now clawed back much of the July 30 damage with the month's 7.5% gain. The next earnings event is scheduled for October 29.
With the next catalyst still two months away, the focus near-term narrows to whether the CEO's sell programme continues at these prices, and whether analysts — who have collectively moved their targets into a tight cluster around $33 — find reason to break from that consensus or tighten it further after any sector-level data.
See the live data behind this article on ORTEX.
Open WAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
